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S320 Poster Session Iwhen compared to pts with normal NS (19.367.8 days, P5\.0001)
and mildly compromised NS (19.568.8 days, P 5\.0001).
Conclusions: Pts with a normal NS prior to transplantation, as de-
fined by the VA-NSCS, have a superior survival rate than pts with
compromised NS prior to APBSCT. Additional studies will be nec-
essary to corroborate the value of the VA-NSCS in determining tox-
icity and outcome after APBSCT.
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BK VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS IN PEDIATRIC HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
Ardura, M.I.1, DeMasi, J.2, Pavlock, T.2, Simms-Waldrip, T.2, Cox, J.3,
Koh, A.Y.2, Aquino, V.M.2 1Nationwide Children’s Hospital & The Ohio
State University, Columbus, OH; 2Children’s Medical Center Dallas &
UT Southwestern Medical Center, Dallas, TX; 3Huntsville Hospital for
Women and Children, Huntsville, AL
Background: BK Virus-associated hemorrhagic cystitis (BKHC)
has emerged as a serious infection after HSCT, however data in chil-
dren are limited.
Objective: To describe the clinical characteristics, treatment, and
outcomes of BKHC in children after HSCT.
Patients and Methods: Retrospective review of medical records of
children who underwentHSCTat Children’sMedical CenterDallas
from Jan 1, 2006 – July 31, 2011 with evidence of BKHC. Demo-
graphic, clinical, microbiologic, management, and outcome data
was collected.
Results: 20 children (incidence 13%), 9 males, median age 11 y
[range 5-18], developed BKHC a median of 15 days [-2 to 57] post
autologous (1) and allogeneic (19) HSCT: MRD (6), MUD (6),
MMUD (6), syngeneic (1) for ALL (7), AML (4), aplastic anemia
(4), and other conditions (5). Conditioning included busulfan/cyclo-
phosphamide/ATG (10), TBI/thiotepa/cyclophosphamide (9), &
carboplatin, etoposide, melphalan (1). Only 8 (40%) patients had en-
grafted and 7 (35%) were receiving systemic corticosteroids at
BKHC onset. 7 (35%) patients complained of dysuria; 15 (75%)
had moderate to large blood on initial urinalysis, all had BK viruria,
14 (70%) had$ 106 BK copies/mL urine. 6 (30%) had BK viremia at
HC onset, 16 (80%) developed viremia with median peak BK of 10,
850 copies/mL blood [439-1.5 million] on D+42 (7-91), resolving in
11/16 by D+76 [22-134]. There was no correlation between viruria
and viremia at onset (Spearman R 0.41, p 5 0.07). 8 (40%) had ab-
normal initial ultrasounds (5 echogenic debris/clot, 4 bladder wall
thickening). Patients had grade 1 (4), 2 (6), 3 (4), and 4 (6) HC. 14
(70%) patients were already receiving fluoroquinolone prophylaxis
at BKHC onset; 17 (85%) patients received Cidofovir at 1 mg/kg
3x/wk (11), 3mg/kg qwk (1), or 5mg/kg qwk (5) for a median of 62
days [1-119]. 6 (30%) patients developed renal insufficiency requir-
ing CVVH, one patient developed Fanconi’s syndrome; 2 (10%) had
urological interventions for obstruction and bleeding. 7 children
died from other causes. Concomitant infections included: bacter-
emia (5), candidemia (3), peritonitis (2), UTI (2), detectable CMV
(5), EBV (2), and adenovirus (4) viremia.
Conclusions: Incidence of BKHC was high in our HSCT popula-
tion, with most children presenting pre-engraftment. Though
many had clinical and virological resolution, morbidity was not neg-
ligible. Additional data in pediatric BKHC after HSCT is needed to
guide optimal treatment guidelines.308
SAFETY OF PROBIOTIC USAGE IN CHILDREN UNDERGOING HEMATOPOI-
ETIC CELL TRANSPLANTATION (HCT): A PRELIMINARY REPORT
Nieder, M.L.1, Hamblin, F.L.1, Gates, M.S.1, Bhatia, M.2, Petrovic, A.1,
Ladas, E.J.2 1All Children’s Hospital, St Petersburg, FL; 2Columbia Uni-
versity, New York, NY
Myeloablative chemotherapy is associated with prolonged periods
of cachexia/anorexia, nausea/vomiting, mucositis, and compromised
gut integrity (CGI). The toxicities associated with HCT often lead
to prolonged periods of poor oral intake andmay result in overt mal-
nutrition. CGI decreases oral tolerance to foods, reduces QOL and
functional status, delays the transition from the hospital to home set-
ting, and increases the risk of the development of gut-derived infec-tions. CGI may increase the risk of acute graft versus host disease.
Probiotics have emerged as a possible therapeutic agent in preserving
gut integrity. Probiotics can improve the gut dysbiosis, promote cell
survival, improve barrier function, prevent adherence of pathogenic
bacteria, and suppress proinflammatory cytokines. Clinical trials in
adults receiving organ transplants have found that probiotics de-
crease the incidence of infection, decrease the duration of antibiotic
use, and decrease the incidence ofmultiorgan failure and systemic in-
flammation. However, the safety and feasibility of probiotics has not
been investigated among children and adolescents undergoing
HCT. Our ongoing 30-patient trial aims to evaluate/investigate:
-Safety of orally administered Lactobacillus plantarum in children
undergoing myeloablative HCT
-Feasibility of administering the probiotic
-Overall incidence of probiotic bacteremia
-Overall incidence of acute GVHD in patients who received pro-
biotic
Lactobacillus plantarum (strains 299 and 299v; 1 x108 CFU/kg/day)
was given orally or via enteral tube daily from Day -7 through Day +
14 to 7 children. No patients had probiotic bacteremia, 2/7 had non-
lactobacillus bacteremia, 3/7 had C. diff in their stool and all patients
survived through Day + 100. Compliance was excellent. There were
no SAE’s. One unexpected adverse event(AE), acute appendicitis, oc-
curred on Day + 21; pathology showed a mixed, mostly gram-nega-
tive flora and the patient hadC.diff. This AEwas not considered to be
attributable to lactobacillus administration. These preliminary re-
sults suggest that it is feasible to administer this probiotic and lacto-
bacillus bacteremia has not been identified. There are no SAE’s to
date and no Grade 2-4 GVH by Day 28.
Table 1. Preliminary Findings
Age in Non-lactobacillus C.diff by GVH by
Years Donor Compliance SAE bacteremia Day 28 Day 28PT 1 2.11 UCB 91% No Yes Yes 0
PT 2 3.7 MUD 100% No No No 0
PT 3 17 MRD 100% No No Yes 0
PT 4 8.5 MRD 100% No No No 0
PT 5 4 MRD 100% No No Yes 0
PT 6 8.5 UCB 100% No Yes No II
PT 7 3.1 MUD 91% No No No 0309
LOWER BIOAVAILABILITY AND SHORTER HALF-LIFE OF VORICONAZOLE
IN PEDIATRIC BMT PATIENTS
Han, K.1, Windreich, R.2, Venkataramanan, R.1, Rivett, J.2, Zhao, W.1,
Goyal, R.K.2 1University of Pittsburgh, Pittsburgh, PA; 2Children’s Hos-
pital of Pittsburgh, Pittsburgh, PA
Introduction: Voriconazole, a triazole antifungal agent with excel-
lent oral bioavailability has been used for mold prophylaxis in trans-
plant recipients. Lack of detailed pharmacokinetic information in the
pediatric BMT setting has been an impediment to optimal dosing
regimen of this agent in children.
Materials & Methods: Voriconazole pharmacokinetics (PK) pro-
files were evaluated in 20 allogeneic BMT patients. Mean age at
transplant was 9.4 y (0.4-22 y); 12 females, 8 males; all whites. All pa-
tients received initial dose of 7 mg/kg twice daily; doses were ad-
justed to achieve Ctrough $1 mcg/ml. For each patient, eight timed
blood samples were collected on three occasions at steady-state:
the first while on an oral dosing (d-10 to d+2), the second while on
intravenous dosing (d+6 to d+26), and the third after switching to
an oral dosing (d+19 to d+110). Voriconazole plasma concentrations
were measured using HPLC. Pharmacokinetic analysis was per-
formed using NONMEM.
Results: In 54 PK studies, the mean trough concentrations of vori-
conazole before (C0) and at the end of dosing interval (C12) were 1.3,
and 1.2 ug/ml, respectively. Less than half of the voriconazole plasma
concentrations (45.4%) were maintained within 1-6 mg/ml, while
46.2% were below 1mg/ml and 8.4% above 6mg/ml. Voriconazole
concentrations normalized to dose (mean6SD, ng/mL/mg) were:
C0 0.00660.008, Cmax 0.03160.022 and C12 0.004 60.005 ug/ml.
C0 and C12 were similar and correlated well (r
2 5 0.88) indicating
Poster Session I S321achievement of steady state. The half life (t1/2) of voriconazole was
5.0965.15 hours. The dose normalized (per mg) AUC (mg*hr/ml)
was 0.11160.081. Voriconazole dose did not correlate with
AUCo-N (r2 5 0.028). There was a good correlation between
AUCo-N and Ctrough (r
2 5 0.94). Population estimates of bioavail-
ability, clearance, apparent volume of the central compartment (Vc)
and apparent volume of peripheral compartment (Vp) were 46.5%,
5.76L/hr, 19.4L and 58.8L.
Conclusions: The bioavailability of voriconazole was significantly
lower in pediatric BMT patients than in non-transplant adult sub-
jects. The t1/2 at steady state tended to be lower than adult patients.
Our study suggests that pediatric patients may require dosing higher
than 7mg/kg twice daily. The wide individual variability and the lack
of correlation between dose and AUC support therapeutic monitor-
ing of voriconazole and dose adjustments based on steady state blood
levels.
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SAFETY AND EFFICACY OF INTRAVENOUS PENTAMIDINE IN CHILDREN
AND ADOLESCENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
DeMasi, J.1, Cox, J.2, Koh, A.1,3, Aquino, V.M.1,3 1Children’s Medical
Center Dallas, Dallas, TX; 2The Huntsville Hospital for Women and
Children, Huntsville, AL; 3University of Texas Southwestern Medical
Center at Dallas, Dallas, TX
Background: Pneumocystis carnii pneumonia (PCP) is a potentially
life-threatening but preventable infection thatmay occur after hema-
topoietic stem cell transplantation (HSCT). Although prophylaxis
with trimethoprim-sulfamethoxazole has been shown to be effective
in the prevention of PCP, the development of neutropenia limits its
use in the early post-transplant period. Aerosolized pentamidine is
a commonly used second line agent, but the need to have the drug
administered via respiratory route may increase the risk of infection.
Intravenous pentamidine has been used in the prevention of PCP in
the post-transplant period, although there are few trials published in
the literature evaluating its safety and efficacy. A recent series study-
ing the use of intravenous pentamidine as secondary prophylaxis in
children with cancer receiving conventional chemotherapy reported
a breakthrough rate of 1.3%.We evaluated the overall efficacy of in-
travenous pentamidine, toxicity profile, and overall impact in the
prevention of PCP in HSCT recipients.
Patients and Methods: Retrospective review of medical records of
children who underwent HSCT from Jan 1, 2005 – October 1, 2011
who received intravenous pentamidine as first line PCP prophylaxis
initiated at admission. Demographic, clinical, microbiologic, man-
agement, and outcome data was collected.
Results: 170 consecutive pediatric patients were given intravenous
pentamidine before myeloablation and then every 28 days until the
subject was 6 months post-HSCT, had stable neutrophil recovery
(ANC.1000 without growth factor support), had discontinued im-
munosuppression and did not have evidence of chronic graft versus
host disease.). No cases of PCP were seen in this cohort. Ten (6%)
had a grade I side effect of nausea/vomiting requiring slower infusion
time and 2 (1%) had a grade IV reaction with anaphylaxis and hypo-
tension requiring transfer to the intensive care unit for management.
Conclusions: Our pediatric HSCT patients receiving pentamidine
had no episodes of breakthrough PCP, and the incidence of side ef-
fects was low. Given the potential neutropenic effects of trimetho-
prim-sulfamethoxazole, compliance with drug administration, and
inferior efficacy of other PCP prophylactic medications, intravenous
pentamidine should be considered as first line therapy in the preven-
tion of PCP in children undergoing HSCT.312
IDENTIFYING RELIGIOUS/SPIRITUAL (R/S) PERSPECTIVES OF ADOLES-
CENTS AND YOUNG ADULTS RECEIVING BLOOD AND MARROW TRANS-
PLANT: A QUALITATIVE STUDY
Hegner, M.A., Ragsdale, J.R., Grossoehme, D.H., Mueller, M.,
Davies, S.M. Cincinnati Children’s Hospital Medical Center, Cincinnati,
OHBone marrow transplant (BMT) or hematopoietic stem-cell trans-
plantation (HSCT) are difficult treatments for life threatening ill-
nesses; the emotional stress experienced by patients of any age is
high. Religion/spirituality (R/S) is commonly used by Americans, in-
cluding adolescents, to cope. Religion can be described as a personal
or communal system of religious attitudes, practices and beliefs.
Spirituality is generally described as the feelings, experiences, and
practices that arise from the search for the sacred or God. We hy-
pothesize that the experience of illness and BMT would affect
what adolescents and young adults (A/YA) believe about R/S and
their way of using faith to make meaning and to cope. The specific
aim was to understand from the patients’ perspective how they use
R/S and how their R/S changes in the course of their BMT experi-
ence. Our goal is to develop a conceptual model of how R/S con-
structs operate in the experiences of A/YA undergoing BMT and
also begin to develop an empirically-based pastoral care interven-
tion. This is a qualitative study of R/S in persons aged 13-29 years
undergoing HSCT or BMT. Semi-structured interviews are com-
pleted in the first 100 days post-transplant and at 1- year post-trans-
plant. Interviews are audiotaped, transcribed, and coded for common
themes using grounded theory methodology. Seven interviews (50%
of those eligible) have been completed. Preliminary analysis shows
that prayer is themost commonly used R/S practice, and that thema-
jority of participants believe that their illnesses are ‘‘part of God’s
plan’’. Without the development of evidence for clinical practice,
chaplains may offer care which may or may not be effective. We
will propose a conceptual model suitable for future testing, and ulti-
mately contribute to a better psycho- social- and spiritual- outcomes
for A/YA undergoing BMT or HSCT.313
DRUG INTERACTION BETWEEN ORAL VORICONAZOLE AND ORAL
CALCINEURIN INHIBITOR AND ITS RELATIONSHIP WITH BLOOD CON-
CENTRATION OF VORICONAZOLE IN RECIPIENTS OF ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Sadahira, K., Mori, T., Kato, J., Yamane, A., Okamoto, S. Keio Univer-
sity School of Medicine, Tokyo, Japan
Background: Drug interaction between calcineurin inhibitors (cy-
closporine A (CsA) and tacrolimus) and voriconazole is well known.
However, it has yet to be fully evaluated in the setting of hematopoi-
etic stem cell transplantation (HSCT). We have previously shown
a wide variability in the drug interaction between voriconazole and
calcineurin inhibitors in HSCT recipients, which led to a conclusion
that uniform reduction of the dose of calcineurin inhibitors was not
recommended on initiating voriconazole. However, in that study,
the route of administration of both drugs was not taken into consid-
eration. In the present study, the magnitude of drug interaction
between oral voriconazole and oral CsA was examined in HSCT
recipients, and its relation with the blood concentration of voricona-
zole was also evaluated.
Patients and Methods: Nineteen recipients of allogeneic HSCT
who had already been on a steady dose of oral CsA, and were started
on oral voriconazole (200 mg per body every 12 h) for the treatment
or prophylaxis of fungal infection could be evaluated. The concen-
tration/dose (C/D; (ng/ml)/(mg/kg)) ratio of CsA was calculated
7–10 days after initiating voriconazole when the increased blood
levels of calcineurin inhibitors had stabilized. The plasma level
of voriconazole was measure by high-performance liquid chroma-
tography.
Results: The median C/D ratio of CsA significantly increased to
113.7 (ng/ml)/(mg/kg) (range, 62.4-189.5) after initiating voricona-
zole administration as compared with that before (63.1 (range, 41.1-
189.0): P\0.001). Median increased rate of C/D ratios were 83.0%
with a range of 0.3% to 224.7%. The plasma level of voriconazole
on the day of evaluating C/D ratio was 1.9860.84 mg/ml. The in-
creased rate of C/D ratio of tacrolimus did not correlate with the
plasma level of voriconazole (r 5 -0.17, P 5 0.50).
Conclusion: The magnitude of the drug interaction between oral
CsA and oral voriconazole demonstrates a wide variability, whose in-
creased rate of C/D ratio ranged between 0.3% and over 200%. This
wide variability could not be explained by the bioavailability of vor-
iconazole. The mechanisms of this variability should be explored in
a future study.
